Limits...
Decreased myocardial injury and improved contractility after administration of a peptide derived against the alpha-interacting domain of the L-type calcium channel.

Viola HM, Jordan MC, Roos KP, Hool LC - J Am Heart Assoc (2014)

Bottom Line: Activation of the channel also alters mitochondrial function.In search of the mechanism for the effect, we found that intracellular calcium ([Ca(2+)]i, Fura-2), superoxide production (dihydroethidium fluorescence), mitochondrial membrane potential (Ψm, JC-1 fluorescence), reduced nicotinamide adenine dinucleotide production, and flavoprotein oxidation (autofluorescence) are decreased after application of AID-TAT peptide.Application of AID-TAT peptide significantly decreased infarct size and supported contractility up to 12 weeks postcoronary artery occlusion as a result of a decrease in metabolic demand during reperfusion.

View Article: PubMed Central - PubMed

Affiliation: School of Anatomy, Physiology and Human Biology, The University of Western Australia, Crawley, WA, Australia (H.M.V., L.C.H.).

Show MeSH

Related in: MedlinePlus

AID‐TAT peptide decreases infarct size and supports contractility in vivo. A, Representative sections from rat hearts treated with 1 μmol/L of scrambled (AID(S)‐TAT) or active (AID‐TAT) peptides. Infarct size is assessed as area that did not take up nitroblue tetrazolium dye. B, Mean±SEM of infarct size in hearts following myocardial infarction expressed as a percentage (%) of total left ventricular (LV) area for all hearts treated with 1 or 10 μmol/L of AID(S)‐TAT or AID‐TAT peptide as indicated. C, Mean±SEM of heart/body weight ratio (Hwt/Bwt) for all hearts treated with 10 μmol/L of AID(S)‐TAT or AID‐TAT peptide as indicated. D, Mean±SEM of left ventricular systolic pressure (LVSP) for all hearts treated with 10 μmol/L of AID(S)‐TAT or AID‐TAT peptide as indicated. E, Mean±SEM of maximum dP/dt for all hearts treated with 10 μmol/L of AID(S)‐TAT or AID‐TAT peptide as indicated. F, Mean±SEM of systolic and diastolic arterial blood pressure (BP) for all animals treated with 1 or 10 μmol/L of AID‐TAT peptide as indicated. n represents number of animals. AID indicates alpha‐interacting domain; TAT, transactivator of transcription.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4309103&req=5

fig08: AID‐TAT peptide decreases infarct size and supports contractility in vivo. A, Representative sections from rat hearts treated with 1 μmol/L of scrambled (AID(S)‐TAT) or active (AID‐TAT) peptides. Infarct size is assessed as area that did not take up nitroblue tetrazolium dye. B, Mean±SEM of infarct size in hearts following myocardial infarction expressed as a percentage (%) of total left ventricular (LV) area for all hearts treated with 1 or 10 μmol/L of AID(S)‐TAT or AID‐TAT peptide as indicated. C, Mean±SEM of heart/body weight ratio (Hwt/Bwt) for all hearts treated with 10 μmol/L of AID(S)‐TAT or AID‐TAT peptide as indicated. D, Mean±SEM of left ventricular systolic pressure (LVSP) for all hearts treated with 10 μmol/L of AID(S)‐TAT or AID‐TAT peptide as indicated. E, Mean±SEM of maximum dP/dt for all hearts treated with 10 μmol/L of AID(S)‐TAT or AID‐TAT peptide as indicated. F, Mean±SEM of systolic and diastolic arterial blood pressure (BP) for all animals treated with 1 or 10 μmol/L of AID‐TAT peptide as indicated. n represents number of animals. AID indicates alpha‐interacting domain; TAT, transactivator of transcription.

Mentions: Rats underwent coronary artery ligation, and within 5 minutes after commencement of reperfusion, 1 or 10 μmol/L of AID‐TAT peptide or AID(S)‐TAT peptide was injected into the LV. The chest was closed, and rats were allowed to recover for up to 12 weeks. In a group of rats, saline was injected instead of peptide (“saline”), and in another group of rats, the chest was opened and closed without undergoing cardiac surgery and rats were allowed to recover (“sham”). Before sacrifice, ventricular function (LVPs and ±dP/dT) was assessed after catheterization of the LV. At the time of sacrifice, hearts were excised and weighed and infarct size was assessed. Consistent with our ex vivo data, rats treated with 1 or 10 μmol/L of AID‐TAT peptide had significantly smaller infarcts than rats treated with AID(S)‐TAT peptide (Figure 8A and 8B). This was evident at 6 and 12 weeks after CAL (Figure 8B). At 12 weeks, heart/body weight ratios were larger in rats treated with AID(S)‐TAT, compared to rats treated with AID‐TAT peptide (Figure 8C). More important, left ventricle systolic pressure LVSP (Figure 8D) and max dP/dT (Figure 8E) were significantly improved at 12 weeks post‐CAL in rats treated with 10 μmol/L of AID‐TAT peptide. Because the AID‐TAT peptide also binds the smooth muscle isoform of ICa‐L, we tested whether the peptide acutely altered arterial blood pressure in rats. After dual catheterization of the femoral artery and LV, rats were injected intravenously with 1 μmol/L of AID‐TAT. Both the arterial and LV blood pressures were recorded over 30 minutes. After 30 minutes, 10 μmol/L of AID‐TAT was injected and both pressures were recorded for a further 60 minutes. No change in arterial pressure was observed in the rats (Figure 8F).


Decreased myocardial injury and improved contractility after administration of a peptide derived against the alpha-interacting domain of the L-type calcium channel.

Viola HM, Jordan MC, Roos KP, Hool LC - J Am Heart Assoc (2014)

AID‐TAT peptide decreases infarct size and supports contractility in vivo. A, Representative sections from rat hearts treated with 1 μmol/L of scrambled (AID(S)‐TAT) or active (AID‐TAT) peptides. Infarct size is assessed as area that did not take up nitroblue tetrazolium dye. B, Mean±SEM of infarct size in hearts following myocardial infarction expressed as a percentage (%) of total left ventricular (LV) area for all hearts treated with 1 or 10 μmol/L of AID(S)‐TAT or AID‐TAT peptide as indicated. C, Mean±SEM of heart/body weight ratio (Hwt/Bwt) for all hearts treated with 10 μmol/L of AID(S)‐TAT or AID‐TAT peptide as indicated. D, Mean±SEM of left ventricular systolic pressure (LVSP) for all hearts treated with 10 μmol/L of AID(S)‐TAT or AID‐TAT peptide as indicated. E, Mean±SEM of maximum dP/dt for all hearts treated with 10 μmol/L of AID(S)‐TAT or AID‐TAT peptide as indicated. F, Mean±SEM of systolic and diastolic arterial blood pressure (BP) for all animals treated with 1 or 10 μmol/L of AID‐TAT peptide as indicated. n represents number of animals. AID indicates alpha‐interacting domain; TAT, transactivator of transcription.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4309103&req=5

fig08: AID‐TAT peptide decreases infarct size and supports contractility in vivo. A, Representative sections from rat hearts treated with 1 μmol/L of scrambled (AID(S)‐TAT) or active (AID‐TAT) peptides. Infarct size is assessed as area that did not take up nitroblue tetrazolium dye. B, Mean±SEM of infarct size in hearts following myocardial infarction expressed as a percentage (%) of total left ventricular (LV) area for all hearts treated with 1 or 10 μmol/L of AID(S)‐TAT or AID‐TAT peptide as indicated. C, Mean±SEM of heart/body weight ratio (Hwt/Bwt) for all hearts treated with 10 μmol/L of AID(S)‐TAT or AID‐TAT peptide as indicated. D, Mean±SEM of left ventricular systolic pressure (LVSP) for all hearts treated with 10 μmol/L of AID(S)‐TAT or AID‐TAT peptide as indicated. E, Mean±SEM of maximum dP/dt for all hearts treated with 10 μmol/L of AID(S)‐TAT or AID‐TAT peptide as indicated. F, Mean±SEM of systolic and diastolic arterial blood pressure (BP) for all animals treated with 1 or 10 μmol/L of AID‐TAT peptide as indicated. n represents number of animals. AID indicates alpha‐interacting domain; TAT, transactivator of transcription.
Mentions: Rats underwent coronary artery ligation, and within 5 minutes after commencement of reperfusion, 1 or 10 μmol/L of AID‐TAT peptide or AID(S)‐TAT peptide was injected into the LV. The chest was closed, and rats were allowed to recover for up to 12 weeks. In a group of rats, saline was injected instead of peptide (“saline”), and in another group of rats, the chest was opened and closed without undergoing cardiac surgery and rats were allowed to recover (“sham”). Before sacrifice, ventricular function (LVPs and ±dP/dT) was assessed after catheterization of the LV. At the time of sacrifice, hearts were excised and weighed and infarct size was assessed. Consistent with our ex vivo data, rats treated with 1 or 10 μmol/L of AID‐TAT peptide had significantly smaller infarcts than rats treated with AID(S)‐TAT peptide (Figure 8A and 8B). This was evident at 6 and 12 weeks after CAL (Figure 8B). At 12 weeks, heart/body weight ratios were larger in rats treated with AID(S)‐TAT, compared to rats treated with AID‐TAT peptide (Figure 8C). More important, left ventricle systolic pressure LVSP (Figure 8D) and max dP/dT (Figure 8E) were significantly improved at 12 weeks post‐CAL in rats treated with 10 μmol/L of AID‐TAT peptide. Because the AID‐TAT peptide also binds the smooth muscle isoform of ICa‐L, we tested whether the peptide acutely altered arterial blood pressure in rats. After dual catheterization of the femoral artery and LV, rats were injected intravenously with 1 μmol/L of AID‐TAT. Both the arterial and LV blood pressures were recorded over 30 minutes. After 30 minutes, 10 μmol/L of AID‐TAT was injected and both pressures were recorded for a further 60 minutes. No change in arterial pressure was observed in the rats (Figure 8F).

Bottom Line: Activation of the channel also alters mitochondrial function.In search of the mechanism for the effect, we found that intracellular calcium ([Ca(2+)]i, Fura-2), superoxide production (dihydroethidium fluorescence), mitochondrial membrane potential (Ψm, JC-1 fluorescence), reduced nicotinamide adenine dinucleotide production, and flavoprotein oxidation (autofluorescence) are decreased after application of AID-TAT peptide.Application of AID-TAT peptide significantly decreased infarct size and supported contractility up to 12 weeks postcoronary artery occlusion as a result of a decrease in metabolic demand during reperfusion.

View Article: PubMed Central - PubMed

Affiliation: School of Anatomy, Physiology and Human Biology, The University of Western Australia, Crawley, WA, Australia (H.M.V., L.C.H.).

Show MeSH
Related in: MedlinePlus